DK277985D0 - Glycoprotein med antitumoral virkning og fremgangsmaade til fremstilling deraf - Google Patents

Glycoprotein med antitumoral virkning og fremgangsmaade til fremstilling deraf

Info

Publication number
DK277985D0
DK277985D0 DK277985A DK277985A DK277985D0 DK 277985 D0 DK277985 D0 DK 277985D0 DK 277985 A DK277985 A DK 277985A DK 277985 A DK277985 A DK 277985A DK 277985 D0 DK277985 D0 DK 277985D0
Authority
DK
Denmark
Prior art keywords
glycoprotein
antitumoral
preparing
procedure
antitumoral effect
Prior art date
Application number
DK277985A
Other languages
English (en)
Other versions
DK277985A (da
DK166626B1 (da
Inventor
Franz Jansen
Pierre Gros
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8409703A external-priority patent/FR2566271B1/fr
Priority claimed from FR8502067A external-priority patent/FR2577137B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DK277985D0 publication Critical patent/DK277985D0/da
Publication of DK277985A publication Critical patent/DK277985A/da
Application granted granted Critical
Publication of DK166626B1 publication Critical patent/DK166626B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK277985A 1984-06-20 1985-06-19 Antitumorale glycoproteiner, hvis kulhydratenheder er blevet modificeret, og fremgangsmaade til fremstilling deraf. DK166626B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8409703 1984-06-20
FR8409703A FR2566271B1 (fr) 1984-06-20 1984-06-20 Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
FR8502067A FR2577137B1 (fr) 1985-02-13 1985-02-13 Glycoproteines antitumorales, modifiees sur leurs motifs glucidiques
FR8502067 1985-02-13

Publications (3)

Publication Number Publication Date
DK277985D0 true DK277985D0 (da) 1985-06-19
DK277985A DK277985A (da) 1985-12-21
DK166626B1 DK166626B1 (da) 1993-06-21

Family

ID=26224020

Family Applications (1)

Application Number Title Priority Date Filing Date
DK277985A DK166626B1 (da) 1984-06-20 1985-06-19 Antitumorale glycoproteiner, hvis kulhydratenheder er blevet modificeret, og fremgangsmaade til fremstilling deraf.

Country Status (14)

Country Link
EP (1) EP0172045B1 (da)
JP (1) JPS6112628A (da)
KR (1) KR930000058B1 (da)
AT (1) ATE40700T1 (da)
AU (1) AU593211B2 (da)
CA (1) CA1248874A (da)
DE (1) DE3568167D1 (da)
DK (1) DK166626B1 (da)
ES (1) ES8605681A1 (da)
GR (1) GR851497B (da)
IE (1) IE58514B1 (da)
IL (1) IL75484A0 (da)
NZ (1) NZ212439A (da)
PT (1) PT80662B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
FR2602682B1 (fr) * 1986-08-12 1988-12-02 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5250532A (en) * 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
GB9808485D0 (en) * 1998-04-21 1998-06-17 Univ Cambridge Tech Improvements relating to immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤

Also Published As

Publication number Publication date
IE58514B1 (en) 1993-10-06
KR860000315A (ko) 1986-01-28
EP0172045A1 (fr) 1986-02-19
PT80662B (en) 1986-12-09
AU593211B2 (en) 1990-02-08
ATE40700T1 (de) 1989-02-15
EP0172045B1 (fr) 1989-02-08
JPS6112628A (ja) 1986-01-21
KR930000058B1 (ko) 1993-01-06
IL75484A0 (en) 1985-10-31
GR851497B (da) 1985-11-25
ES8605681A1 (es) 1986-04-01
JPH0582400B2 (da) 1993-11-18
AU4364685A (en) 1986-01-02
NZ212439A (en) 1989-01-27
DE3568167D1 (en) 1989-03-16
PT80662A (en) 1985-07-01
ES544337A0 (es) 1986-04-01
CA1248874A (en) 1989-01-17
DK277985A (da) 1985-12-21
DK166626B1 (da) 1993-06-21
IE851511L (en) 1985-12-20

Similar Documents

Publication Publication Date Title
GR3006689T3 (da)
PT73259A (en) Process for preparing novel substituted pyrazinyl-1,2,4-oxadiazole-5-ones
DK277985A (da) Glycoprotein med antitumoral virkning og fremgangsmaade til fremstilling deraf
JPS57134465A (en) Manufacture of 1,5-didesoxy-1,5-imino-d- glucitol or n-derivative thereof
AU573531B2 (en) Human lymphotoxin
IL75133A (en) Process for the preparation of 1,2-diacyl-s,n-glycerophosphocholines(or glycerophosphoethanolamines)and some novel intermediates therefor
GR3005079T3 (da)
SE8104482L (sv) Forfarande for framstellning av ett faktor viii (ahf)-hogkoncentrat
IE890607L (en) Antihypertensive hyperimmune milk, production, composition, and use
EP0244189A3 (en) Human pancreatic elastase i
ES8705496A1 (es) Procedimiento para aislar poliarilensulfuros
KR860007963A (ko) 석류석의 선광방법
DE3161613D1 (en) Process for the production of 3-mercapto-propanediol-(1,2)
JPS5241605A (en) Coal gasification apparatus
FR2557126B1 (fr) Procede de production de noirs de carbone au four
JPS5214518A (en) Process for manufacturing a rotatable drum for the centrifugal separat or for concentrating uranium
DE3270177D1 (en) Process for purifying elastase
JPS52791A (en) Dry process for treatment of granular sulfur
JPS57192330A (en) Manufacture of 3,3-dimethylglutaric acid
JPS51139680A (en) Method for purifing enzyme
YU42730B (en) Process for achieving low sulfur concentrations (below 0.02%) in directly reduced iron
Gershkovich et al. Refining Copper from Hydrogen by Blowing Off with an Inert Gas
KRUGER et al. INFLUENCE OF CONTAMINATION BY PLASTER ON CERAMIC SHAPING IN THE FIRM VEB HENNEBERG-PORZELLAN
ZA818604B (en) Process for the treatment of coals of high water content,in particular brown coal
JPS5223361A (en) Process for controlling a gas concentration in a conservatory

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed